Shots:

• Presage and BMS enter into a research collaboration to assess early stage oncology targets in P-0 studies by evaluating patients' unique responses to micro doses of multiple cancer therapies
• The focus of the collaboration is to expand the use of Presage’s CIVO technology in P-0 studies and is the third partnership of Presage for utilizing its CIVO platform to investigate tumor cell and microenvironment responses of therapies in P-0 studies
• CIVO is a micro dosing platform that enables simultaneous assessment of responses for multiple cancer therapies or combinations therapies directly in a single tumor while still in a patient's body

Click here to­ read full press release/ article

Ref: PRNewswire | Image: BMS